CURI vs NMAX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

CURI

35.2
AI Score
VS
CURI Wins

NMAX

62.3
AI Score

Investment Advisor Scores

CURI

35score
Recommendation
AVOID NEW MONEY

NMAX

62score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric CURI NMAX Winner
Forward P/E 8.0645 24.4499 CURI
PEG Ratio 0 0 Tie
Revenue Growth 22.3% 16.5% CURI
Earnings Growth 1400.0% 0.0% CURI
Tradestie Score 35.2/100 62.3/100 NMAX
Profit Margin 0.0% -3.1% CURI
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD NMAX

Relative Price Performance (Last 90 Days)

CURI 1M: -13.9% · 3M: -13.9% NMAX 1M: -27.1% · 3M: -14.8%

Current Technical Phase

CURI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 35

RSI (14): 35.2 · Price: $2.41

NMAX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.1%), weak momentum, RSI 34

RSI (14): 33.9 · Price: $7.55

Fundamentals Snapshot

Metric CURI NMAX
Market Cap — —
Forward P/E 7.8 35.1
Trailing P/E — 388.5
Revenue (TTM) — —
Revenue Growth 0.2% 0.2%
Gross Margin 0.6% 0.4%
Operating Margin 0.4% 0.0%
EPS 0.00 0.02
Dividend Yield 0.13% —

Frequently Asked Questions

Based on our detailed analysis, CURI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.